Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Daiichi Sankyo Inc. |
---|---|
Information provided by: | Daiichi Sankyo Inc. |
ClinicalTrials.gov Identifier: | NCT00185094 |
To examine the effect of three different blood pressure medications on the insulin sensitivity in overweight patients with high blood pressure.
Condition | Intervention | Phase |
---|---|---|
Hypertension Insulin Resistance Metabolic Syndrome |
Drug: Olmesartan medoxomil Drug: Losartan potassium Drug: Atenolol |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | The Effects of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on Insulin Sensitivity in Overweight and Obese Subjects With Hypertension |
Estimated Enrollment: | 60 |
Study Start Date: | February 2004 |
Estimated Study Completion Date: | July 2005 |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Alabama | |
Birmingham, Alabama, United States | |
United States, California | |
San Diego, California, United States | |
United States, Florida | |
Miami, Florida, United States | |
United States, Indiana | |
Indianapolis, Indiana, United States | |
United States, Maryland | |
Baltimore, Maryland, United States | |
United States, Massachusetts | |
Boston, Massachusetts, United States | |
United States, Minnesota | |
Rochester, Minnesota, United States | |
United States, Pennsylvania | |
Philadelphia, Pennsylvania, United States | |
United States, Texas | |
San Antonio, Texas, United States | |
Dallas, Texas, United States |
Study ID Numbers: | 866-440 |
Study First Received: | September 9, 2005 |
Last Updated: | December 22, 2005 |
ClinicalTrials.gov Identifier: | NCT00185094 |
Health Authority: | United States: Food and Drug Administration |
Obesity Losartan Metabolic Diseases Vascular Diseases Overweight Olmesartan medoxomil Angiotensin II |
Insulin Hyperinsulinism Insulin Resistance Glucose Metabolism Disorders Metabolic disorder Atenolol Hypertension |
Neurotransmitter Agents Sympatholytics Disease Molecular Mechanisms of Pharmacological Action Adrenergic Agents Physiological Effects of Drugs Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions Angiotensin II Type 1 Receptor Blockers |
Pathologic Processes Autonomic Agents Syndrome Therapeutic Uses Adrenergic beta-Antagonists Adrenergic Antagonists Cardiovascular Diseases Anti-Arrhythmia Agents Peripheral Nervous System Agents |